Seminars in Cancer Biology

Article	Citations
Small secretory proteins of immune cells can modulate gynecological cancers	525
Editorial Board	474
Advances in biology and novel treatments of SCLC	377
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	331
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	298
Critical DNA damaging pathways in tumorigenesis	280
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]	254
Emerging applications of bacteria as antitumor agents	251
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	245
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	242
Multifaceted role of chemokines in solid tumors: From biology to therapy	212
Deregulated transcription factors in the emerging cancer hallmarks	211
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	208
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	205
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	199
Editorial Board	197
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	197
Editorial Board	195
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	178
Innovative trial design in precision oncology	176
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	171
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]	167
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	160
Anticancer properties of chimeric HDAC and kinase inhibitors	159
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	158

The IL-1 family in tumorigenesis and antitumor immunity	149
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	146
The emerging role of metabolic interventions in uveal melanoma	146
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies	144
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	140
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	139
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	130
Immune cellular components and signaling pathways in the tumor microenvironment	127
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	125
Genome chaos: Creating new genomic information essential for cancer macroevolution	124
Gut microbes in gastrointestinal cancers	124
Origins and molecular effects of hypoxia in cancer	123
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	122
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]	120
Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine	119
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	119
Editorial Board	118
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	116
Anticancer natural products targeting immune checkpoint protein network	112
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	112
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	112
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	111
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	111
How far have we explored fungi to fight cancer?	111
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis	107
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	107
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	107
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	106
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	106
Atrial fibrillation in cancer patients: Epidemiology, identification and management	106
The role of deiodinases on metabolic alteration in cancer	105
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	103
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	102
Reprogramming of glycolysis by chemical carcinogens during tumor development	101
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	101
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	100
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	98
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	98
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	97
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	97
Editorial Board	93
Editorial Board	93
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	90
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	90
The microbiome-immune cell interaction network: Advancing tumor immunotherapy	89
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	89
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	89
Microbiota and lung cancer	88
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	88
The role of tumor microenvironment and exosomes in dormancy and relapse	85

Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	84
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	83
Editorial Board	82
Analytical demands to use whole-genome sequencing in precision oncology	80
Microorganisms in cancer tertiary lymphoid structure formation	78
The foundational framework of tumors: Gametogenesis, p53, and cancer	77
Metabolic reprogramming of tumor microenviroment by engineered bacteria	77
Clinical utility of whole-genome sequencing in precision oncology	77
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	76
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	76
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	76
The role of RNA processing and regulation in metastatic dormancy	75
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	75
Advancements in small cell lung cancer	74
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	74
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	74
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	73
Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology	72
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	72
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	72
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	72
Holistic immunomodulation for small cell lung cancer	72
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	70
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	70
Anticancer activity of lactic acid bacteria	70
Excess body weight: Novel insights into its roles in obesity comorbidities	70
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	70
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	70
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	68
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	68
Targeting p53 for the treatment of cancer	67
CRISPR/Cas mediated epigenome editing for cancer therapy	66
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	66
Paradoxes of cancer: Survival at the brink	66
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	66
Editorial Board	65
Editorial Board	65
SR-BI as a target of natural products and its significance in cancer	64
Editorial Board	63
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	63
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	63
Microbial metabolites for cancer immunotherapy: Current evidence and future directions	62
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	62
Thematic issue ‘tumor glycolysis’	62
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	62
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	61
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	61
Deregulated transcription factors and poor clinical outcomes in cancer patients	61
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	61
The impact of VEGF on cancer metastasis and systemic disease	60
TGF-β, EMT, and resistance to anti-cancer treatment	60
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	60
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	60
Human cell polyploidization: The good and the evil	60
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	60
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	59
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	59
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	59
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	57
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	57
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	57
Editorial Board	57
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	56
Precision diagnostics in lymphomas – Recent developments and future directions	55
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	54
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	54
Artificial intelligence aids in development of nanomedicines for cancer management	54
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	54
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	54
The intricate nature of senescence in development and cell plasticity	54
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	53
cGAS/STING signalling pathway in senescence and oncogenesis	53
Gut microbiota and immunosenescence in cancer	53
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	53
Transcriptional factors targeting in cancer stem cells for tumor modulation	53
Alternative splicing in EMT and TGF-β signaling during cancer progression	53
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	53
Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases	52
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future	52
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	51

Vitamin D: What role in obesity-related cancer?	51
Editorial Board	50
Editorial Board	49
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	49
Editorial Board	49
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	49
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	48
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	48
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	48
Precision medicine in pediatric solid cancers	48
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	47
Nanoparticles: Attractive tools to treat colorectal cancer	47
Predictive biomarkers for response to immune checkpoint inhibition	47
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	47
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	47
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	47
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	47
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	46
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	46